

Review Article**Targeting oncogenic receptor: From molecular physiology to currently the standard of target therapy****George Zhu^{1*}, Ali-Akbar Saboor-Yaraghi², Yosef Yarden³**¹*The Institute of Oncology, Tehran University of Medical Sciences, Tehran*²*Department of Cellular and Molecular Nutrition School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran*³*Department of clinical Immunology, Weizmann Institute of Science, Rehovot 76100, Israel*

Received: 3 February 2017

Revised: 22 February 2017

Accepted: 24 February 2017

Abstract

In 1989-91, George Zhu first postulate oncogenic receptor, as a result of his experiments in which steroid PML-RARa fusion receptor gene rearrangement within t(15;17) translocation in acute promyelocytic leukemia (APL), and androgen cognating its (AR/ERa signaling or FGFR-1) receptor induced tumours of the breast glands in two aplastic anemia during the course of testosterone treatment (hormonal tumorigenesis). In the past 2-3 decades, there are at least 30 receptor genes involving in various of oncogenic process. These normal physiologic receptors linked to gene amplification, rearrangement, deletion and activating mutations, which converted receptor to oncogenic (also oncogenic receptor) in development, progressive and pathogenesis of benign and malignant diseases. Receptors included nuclear receptor family members (oncogenic estrogen/estrogen receptor alpha signaling, oncogenic androgen receptor, oncogenic pml/RARa, and GR β); Oncogenic growth factor receptors (EGF/ oncogenic receptor EGFR, Neu oncogenic receptor, insulin receptor/c-ros proto-oncogenic receptor, insulin and IGF-1 and -II/oncogenic IGF-1R thrombopoietin (TPO)/TPO receptor. oncogenic MPL receptor, HGF/HGFR, met oncogenic receptor); Cytokine receptor rc family members; Cytokine receptors including the β c family(G-CSF/oncogenic CSF3R, oncogenic EPOR),and oncogenic autocrine growth hormone/nuclear GHR and other VEGFR2. Upon ligand binding or external antigen stimuli, mutated growth factor receptors and mutant cytokine receptors including type I cytokine receptor may be activated via ligand binding receptor complex, receptor dimerizes especially receptor homodimerization, and induces transphosphorylation of tyrosine residues in the cytoplasmic domains which serves as docking sites for several adaptor molecular harboring SH2 domain or phosphotyrosine binding domain. These adaptor molecules recruit and activate downstream signaling molecules such as Ras/MAPK, phospholipase C-r, JAK-STAT molecules, NF-KB pathways through tyrosine- or serine/threonine-phosphorylation. Among them, Ras /MAPK/ERK, PI3-K/akt and STAT pathways act as the major oncogenic signaling pathway. Overall, these receptors coupled with their ligands are key importance in human subtle balance in physiologically regulating multiple cellular processes, for example, in cellular proliferation and differentiation. Oncogenic receptors mutational activation and/or aberrant gene rearrangement are promiscuously interference with normal cell survival, anti-apoptosis and proliferation, and malignant initiation and progression. Others, in a special APL case, oncogenic pml/RARa fusion behave as a potent (constitutive) transcriptional repressor of RAR and retinoic acid signaling, inducing a differentiation blockage at promyelocytic stage which can be overcome with therapeutic doses of 9-cis retinoic acid or ATRA ligand. This is the classical model of retinoic acid action. This encourages receptor normal agonist, and oncogenic receptor antagonists (or inhibitors) target therapy.

Keywords: Receptor; Oncogenic receptor; gene activating mutation and/or aberrant rearrangement; tumours/cancers

Introduction

Since introduction of oncogenic receptor concept by George Zhu from oncogenic pml/RARa fusion in etiology of a specific APL and androgen/androgen receptor oncogenic signaling in role of hormonal tumorigenesis in early 1989s(George Zhu,1989-2016),de The H and Chomienne C

*Address for Corresponding Author:

Prof. George Zhu

The Institute of Oncology, Tehran University of Medical Sciences,
Tehran, Iran

E-mail: sansan4240732@163.com

(Chomienne et al., 1990; de The et al., 1991), at the same period, found that in t(15;17) APL the translocated retinoic acid receptor alpha (an RAR mutant) contribute to leukemogenesis. Neil JC (Neil et al., 1988) is in detail receptor-mediated leukaemogenesis from the oncogenic function of T cell antigen receptor (TCR oncogenic signal) on lymphoid cells not only bind external ligand but are crucial in cellular proliferation. In transgenic mice expressing a mutated TCRbeta lacking the variable chain (Delta V-TCRbeta) developed CD4+, CD8+, IL-2Ra positive T-cell lymphoma (Jacobs et al., 2015). Patients with ataxia-telangiectasia are particularly prone to development of T-cell chronic lymphocytic leukemia with chromosomal abnormalities. The breakpoint is composed of a TCR J alpha chain region (from 14q11) fused to sequences derived from 14q32 but on the centromeric side of the IgCmu (IgH), indicating that a 14:14 translocation (t(14;14) (q11;q32); inv(14)(q11;q32)) in the development of T-cell tumors (Denny et al., 1986; Davey, et al., 1988). Like mutated oncogenic growth factor receptors (Corcos, 1990), antigen-independent B cell receptor (BCR) signaling drives the oncogenic process (Farinha, 2005). The genetic defects in heavy-chain disease (HCD) result in the production of abnormal membrane-associated heavy chain lacking an antigen-binding domain, these aberrant B-cell antigen receptors might engage in ligand-independent signaling, indicating a role in the genesis of HCD neoplasia (Corcos, 1990; Corcos et al., 2011). Thus, BCR associated kinase inhibitors, such as ibrutinib, have revolutionized the treatment of chronic lymphocytic leukemia (CLL) (Jain, et al., 2017).

Yarden Y (Yarden, 1991) propose neu oncogenic receptor from neu oncogene-related receptor tyrosine kinase (RTK), and this might be useful in neu oncogenic receptor (Levea et al., 1993; Tzahar et al., 1998; Houlston et al., 2004; Jonckere et al., 2012; Nicolas, 2015) antagonists lapatinib and trastuzumab target therapy in metastatic breast cancer with HER2V659E mutation (Serra et al., 2013). In a large trials of 48 HER2-positive early breast cancer patients, the adjuvant trastuzumab treatment demonstrates highly favorable outcome. Five-year overall survival rates and disease free survival rates were 95.8% and 93.8% respectively (Kato, 2015). Al-Nedawi (Al-Nedawi et al., 2008) explore the area that microvesicles containing oncogenic receptor EGFRVIII released to cellular surroundings and blood of tumour-bearing mice, and can merge with the plasma membranes of cancer cells lacking EGFRVIII. This intercellular transfer of membrane-derived microvesicles ('oncosomes'-small plasma membrane buds, Robinson (Robinson, 2015) leads to the transfer of oncogenic activity including activation of MAPK and Akt and autocrine activation of its key signaling receptor (VEGF receptor-2), and increases in anchorage-independent growth capacity. Santos (Santos et al.,

2015) studies oncogenic GRPR (gastrin-releasing peptide receptor) in neoplastic multiple signaling pathway. Somatic mutations in cholecystokinin 2 receptor (CCK2R) alter receptor activity that promote oncogenic phenotype, and the importance of evaluating CCK2R inhibitors to block mutant forms of this receptor (Willard et al., 2012). Intriguing, epithelial cell adhesion molecule (EpCAM), as a homophilic adhesion protein, is a novel oncogenic receptor which frequently overexpressed in epithelia, progenitors, embryonic stem cells, carcinoma and cancer-initiating cells, and target its antibodies (Maetzel et al., 2009). The present will in brief focus on recent innovative diagnostic and therapeutic strategies forthcoming in this area.

Steroid hormone receptors oncogenic signaling

Steroid hormones are a biologically related hormones secreted into blood stream by the adrenal cortex and glands (ovaries and testes) (Singh and Kumar, 2005). After releasing into the blood, steroid hormones enter target cells by crossing the cytoplasmic membrane and exert their action by binding to high affinity receptors, also known as steroid hormone receptors. Steroid hormones control a wide variety of cellular function. Sex hormone (androgen and estrogen) play an important role in gonadal (sex determination) development, the formation of the menstrual cycle. At puberty, estradiol induces mammary duct formation. As the hypothalamic-pituitary-ovarian axis matures, there is a brief phase of an ovulatory cycles during which the mammary gland is influenced principally by estrogens. Once ovulation is established, corpus luteum produces progesterone, which stimulate growth of the lobuloalveolar structures. During the reproductive years, progesterone promotes differentiation of alveolar cells into secretory cells, and dilation of the duct system. In conjunction with prolactin and other metabolic hormones, progesterone stimulates lipid droplet formation, and secretory activity. While prolactin and growth hormone are the most important pituitary hormones affecting growth of the mammary gland during pregnancy. It is estradiol and progesterone that prevent the full expression of this secretory effect on the mammary epithelium. At parturition, the sudden withdrawal of these two hormones permits the breast to respond to the lactogenic hormones. Progesterone can acts in synergy with estradiol to prime the mammary gland to respond to mitogens like prolactin, glucocorticoids and growth hormone, which is essential for human alveolar gland development and growth (Horwitz, 1985). Figure 1 represents hormone biosynthetic reaction.

The estrogen receptor (ER) is found in a wide variety of species and is involved in the programming and regulation

of gene expression in vertebrate female sex-accessory tissue (Green & Chambon, 1986). Estrogen E2/ERα signaling plays an important role in the regulation of mammary gland development and function, and also contributes to the onset and progression of breast cancer. More than 70% of human breast cancers express ERα, and elevated levels of ERα in benign breast epithelium correlate with increased risk of breast cancer (Elangovan et al., 2011). Green S & Chambon P (Green & Chambon, 1986) described oncogenic hormone receptor from human oestrogen receptor cDNA sequence. This carcinogenicity of estrogen is attributed to receptor-mediated stimulation of cellular proliferation. Increased proliferation could result in turn in accumulation of genetic damage and stimulation of the synthesis of growth factors that act on the mammary epithelial cells via an autocrine or paracrine loop (Russo et al., 1998). There was evidence that estrogen-dependent cell line (MCF-7) cells under estradiol (E2) stimulation release some known polypeptide growth factor activities (EGF-like, IGF-1-like) (Dickson et al., 1986). Dickson RB and Stancel GM (Dickson & Stancel, 2000) discuss estrogen receptor-mediated processes in normal and cancer cells. ER-mediated regulation of gene expression plays

many significant roles in normal and cancer cells and this will improve the understanding of hormonal carcinogenesis.

Furthermore, Russo (Russo et al., 2002 & 2006) Santen, Cavalieri, Rogan (Santen et al., 2009) and Yager, Yue (Yue et al., 2009; Cavalieri et al., 2002) discussed estrogen receptor-dependent and independent mechanisms of breast carcinogenesis. ERα mediated stimulation of breast cell proliferation with a concomitant enhanced rate of mutations, and estradiol metabolites (see figure 2a) to genotoxic DNA mutation cause DNA damage (figure 2b). Thus, ERα function as estrogen activated transcription factor and involved in the stimulation of estrogen target genes in the regulation of cell cycle progression and growth of breast epithelium (Singh et al., 2005). As Clarke described (Clarke, 2004), some ERα/PR-positive epithelial cells are quiescent breast stem cells that acts as 'steroid hormone sensors'. Such hormone sensor cells are likely to secrete positive or negative paracrine/juxtacrine factors dependent on the prevailing estrogen or progesterone concentration to influence the proliferative activity of adjacent ERα/PR- epithelial cells. This might represent one




Figure 1. Hormones normally biosynthetic reaction




Figure 2(a). Estradiol metabolites reaction. **(2b).** Schematic description of DNA damage mutation following formation of depurinating adduct. Data adapted from Yue et al. (2013).

step toward the development of neoplasia and malignancy-invasive tumors.

Utilizing ERKO/wnt-1 oncogene mice (Bocchinofuso et al., 1997, figure 3) and aromatase/ERKO transgene mice (Tekmal et al, 2005), they demonstrated the role of ERα-dependent in mammary development and carcinogenesis. Lack of ERα mice results in impaired mammary development and much delayed tumor incidence even in the presence of tissue estrogen (50% of mammary tumors at 5 months in ER-positive animals versus 11 months in those without ERα). Whereas introduction ERα into the tTA/TAg mice (Tilli et al., 2003) and DES-treated MT-mER transgene mice (Couse et al., 1997; Davis et al., 2012) developed mammary adenocarcinoma (at 8 months) and preneoplastic lesion atypical hyperplasia (at 4 months), which implicate that ERα contributes to carcinogenic through ER-mediated signal transduction, increasing estrogen-responsive cell proliferation, and ERα signaling in mammary cancer initiation and progression.




Figure 3. The effect of estrogen receptor alpha (ERα) on the development of mammary tumors in Wnt-1 transgenic mice. Data adapted from Bocchinofuso et al., (1997).

Moreover, mutations in estrogen receptor converted estrogen receptor-dependent breast tumor into estrogen-independent growth (Wesledge & McGuire, 1983). Fuqua (Fuqua, et al, 2000) found a K303R estrogen receptor alpha (ERα) mutation in human premalignant breast lesions (figure 4). The K303R mutation formed tumors in nude mice faster than cells expressing wild-type ERα in the presence of low levels of estrogen (at 10-12 M estradiol), and those K303R ERα-expressing tumors are estrogen-independent growth (Herynk et al, 2010). From screening of those ER+ breast cancer, Veeraraghavaa and colleagues (46-47) detected oncogenic ESR1- CCDC170 fusion positive tumors. This neoplastic ESR1-CCDC170 fusion leads to anchorage- independent growth, reduced endocrine sensitivity and enhanced xenograft tumor formation, suggesting a new concept of this oncogenic receptor ESR1 fusion in pathobiology in a more aggressive subtype of breast cancer.

Thus far, in addition to tamoxifen and fulvestrant, AZD9496, a non-steroid small molecule inhibitor of oncogenic(or neoplastic, due to not targeting a normal ERα) ERα (George Zhu, 2007; Elangovan et al., 2011; Tilli et al., 2003; Couse et al., 1997; Frech et al., 2005) bound and down-regulated clinically relevant ESR1 mutants in vitro and inhibited tumor growth in an ESR1 mutant patient-derived xenograft model that included a Y537 and D538G mutation (Takeshita et al., 2015; Weir et al., 2016). AZD9496 is currently being evaluated in a phase I clinical trial (Weir et al., 2016).

Using heterotypic tissue recombination, Cunha (Cunha et al., 1981-2008) established a stromal androgen




Figure 4. Sequence analysis of ER Var and WT cDNAs isolated from frozen breast hyperplastic tissue. A portion of the sequencing products is shown for WT and Var clones, demarcating the location of the G transition and Arg substitution. ER domains A–E and the exons across these domains are shown on the *bottom*, with the location of the Lys-to-Arg change demarcated with a *box* across exon 4 at the end of domain D (Data adapted from Fuque et al. (2000)).

receptor for mesenchymal-epithelial transition (EMT) in normal androgen-dependent prostate development and in the etiology of benign prostatic hyperplasia (Izumi et al., 2013). By different methods including immortalized human prostate cells expressing androgen receptor (Berger et al., 2004) and androgen receptor transgene (Stanbrough et al., 2001), they demonstrated that androgen receptor is oncogenic, and this oncogenic receptor induces prostate intraepithelial neoplasia (PIN) and plays a crucial role in transforming process in prostate cells. The AR-expressing PrECs are dependent on circulating testosterone for tumor growth, and immortalized PrECs lacking AR failed to form tumors. But this androgen receptor is difficult to characterize as an oncogene (Berger et al., 2004). Mononen (Mononen et al., 2000) and Koivisto (Koivisto et al., 2004) detected the R726L mutation of androgen receptor (AR) in Finnish patients with sporadic or familial prostate cancer, which may confer an up to 6-fold increased risk of a small fraction of prostate cancer in Finland. T877A mutation of AR was identified in LNCaP cell line and metastatic cells of androgen-independent prostate cancer (Harris et al., 1990; Veldschnolte et al., 1990; Culing et al., 1993; Goddipati et al., 1994; Suzuki et al., 1996; Southwell et al., 2008), whereas V739M was identified in early stage PCa (Newmark, 1992). Nyquist (Nyquist, 2013) discovered

intragenic AR gene rearrangements in CRPC tissues, rendering expression of truncated AR variants proteins lacking the AR ligand-binding domain, constitutive activity of AR, and intragenic ARv567es cDNA formed tumor faster rate and a CRPC growth independent of full-length AR or androgens. Therefore, targeting oncogenic AR variants (George Zhu, 2013; Berger, 2004; Tepper, 2002; Kung, 2009; Sun, 2010; Young, 2011; Liang, 2015) (here, please note that it is no need to target a normal AR) includes AR antagonists bicalutamide and enzalutamide, which might provide an approach to suppress prostatic intraepithelial neoplasia (PIN) development. In phase II trials, the CBR (clinical benefit rate) of 19% was observed with bicalutamide 150mg daily dose in selected patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer (Gucalp, 2013).

In another area, increased thyroid diseases and thyroid papillary carcinoma (PTC) associated with a high dietary iodine intake (George Zhu, 2013; Coindet, 1821; Goldberg & Chaikoff, 1952; Suzuki et al., 1962; Mussig et al., 2006; Horn-Ross et al., 2001; Giusti et al., 2010; Michikawa et al., 2012; Schneider, 2013; Chandrasekarn et al., 2013; Choi & Kim, 2014).

GRB/STAT-5 pathway was found to be involved in erythrocytosis (Varricchio et al., 2011), and GR/Sgk1 (including GR-Sgk1-FOXO3a signaling pathway and GR-Sgk1-MKPI/DUSP1 pathway) network linked to higher tumor grade and antiapoptotic and increased cancer recurrence (Mikose et al., 2001; Melhem et al., 2009; Isikbay et al., 2014). Moreover, the aberrant glucocorticoid receptor signaling in breast cancer (Mirand, et al., 1953; Lien et al., 2006; Moutsatso et al., 2007; Vilasco et al., 2011), prostate hyper proliferation (Krishnan et al., 2002; Simanaian, 2011), Cushing's disease (Ebisawa et al., 2008) and Nelson's syndrome (Karl et al., 1996). Thus, GR activation is sufficient to provide a potent signal for cell survival in mammary epithelial cells. Induction of serum and glucocorticoid-regulated kinase-1 (SGK-1) expression is required for GR-mediated epithelial cell survival signaling. SGK-1 is a direct GR target and encodes a serine-threonine kinase with significant homology to Akt-1. In immune histochemical analysis, nucleus GR-immunostaining and glucocorticoid receptor (GR)-immunopositive cells were abundantly present in subclinical Cushing's disease due to pituitary adenomas (2 macroadenomas and 8 microadenomas), suggesting impaired glucocorticoid action, at least in part, in tumorigenesis of this disease (Ebisawa et al., 2008). RU486 (mifepristone), a glucocorticoid receptor antagonist, has been successful treatment of the Cushingoid phenotype

with markedly elevated lymphocyte glucocorticoid receptor numbers in a transient Cushing's syndrome (Newfield, 2000; Johanssen et al., 2007). Mifepristone may also be a useful strategy for increasing tumor cell apoptosis in chemotherapy-resistant GR+ triple-negative breast cancer (TNBC) (Skor et al., 2013). In addition, the cortisol/cortisone-responsive AR(AR(ccr)) has two mutations (L701H and T877A) that were detected in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth. GR antagonist RU38486 showed inhibitory activity (Krishnan et al., 2002), but its therapeutic application to treat prostate cancer may be limited. Thus, the combination of ARccr receptor antagonists bicalutamide (casodex) together with a ligand suppressor (triamcinolone) represents a new therapeutic strategy for the treatment of the subset of androgen-independent prostate cancers harboring the L701H or ARccr type.

So there is a conflict among hormone FSH/FSH receptor in etiology of epithelial ovarian cancer (Risch, 1998; Althuis et al., 2004). Actions of FSH (follicle-stimulating hormone) in reproductive physiology are essential for folliculogenesis and steroidogenesis (Richards & Faruukhi, 1978), FSH receptor (FSHR), a transmembrane receptor with a G protein-coupled signaling, is expressed by granulosa cells in developing ovarian follicles. Overexpression of FSHR activates oncogenic pathways through FSHR-induced EGFR amplification, and HER-2/neu and activated ERK1/2 in preneoplastic immortalized ovarian surface epithelial (IOSE) cells (Choi, 2004). The data by

epidemiological studies that an increased occurrence of ovarian cancer has been suggested with exposure to high levels of gonadotropins during postmenopause or infertility therapy (Hull et al., 1996; Shusha et al., 1996; Brinton et al., 2004).

Retinoids can regulate proliferation and differentiation of normal myeloid cells, and that supraphysiological levels of retinoic acid (9-cis RA or all-trans RA) can induce abnormal promyelocytes toward maturation. These leukemic cells harboring steroid PML-RARA translocation play a central role in etiology of APL (George Zhu, 2013, Chomiene, 1990; de The, 1991; Hauksdotti & Privalsky, 2001). The PML-RARa chimera can function as a strong transcriptional repressor of retinoic acid(RA) signaling and RAR function by perturbing normal retinoid signaling, leading to a block in differentiation and in an accumulation of leukemic cells at promyelocytic stage (George Zhu et al., 2013 and 2014; Hauksdotti & Privalsky, 2001; Grignani et al., 1993; Rousselot et al., 1994; Yoshida et al., 1996; Kitareewan et al., 2002; Segalla et al., 2003; Carbone et al., 2006; Nasr et al., 2008; Marstrand et al., 2010; Lallemand-Breitenbach & de The, 2010; Podhorecka et al., 2013; Dos Santos et al., 2013; Humbert et al., 2014; De Brackeleer et al., 2014) (see model, figure 5, George Zhu, 1991, 2013, 2014). This oncogenic receptor is locked in its "off" regulated mode thereby constitutively repressing transcription of genes or key enzymes that are critical for differentiation of hematopoietic cells (George Zhu et al.,




Figure 5. Hypothetical model of the regulation of retinoic acid (RA) action (George Zhu, January 1991, revised in 2012). Schematic alignment of the receptor protein. The two highly conserved regions, identified as the putative DNA-binding (C) and hormone-binding (E), a hinge region (D) and the non-conserved variable NH₂-terminus (A/B) as described above. Data adapted from George Zhu (2013).

2013; Rietveld & Caldenhove, 2001). Moreover, the PML-RAR α apparently involved in part the defects in ability to release corepressor under physiological hormone concentration. The wild-type RAR α readily form heterodimer with the retinoid X receptors (RXRs). In contrast, chimeric pml/RAR α oncoprotein exhibited an enhanced ability to bind to DNA as homodimer. This enhanced homodimerization by RAR chimeras implicates in aberrant corepressor interaction properties of these oncogenic receptor derivatives, influences their DNA recognition, and appears to prevail in neoplastic cells of these oncoproteins (Hauksdotti & Privalsky, 2001). These differences in target gene recognition by the normal and oncogenic RAR α protein may contribute to the leukemogenic phenotype (Hauksdotti & Privalsky, 2001).

Targeting oncogenic growth factor receptors

The EGF receptor (EGFR) (Cohen et al., 1982; Brown et al., 1989) has a key role in normal embryonic development, adult tissue homeostasis and many pathological processes, particular tumor formation. Aberrant EGFR activation becomes oncogenic due to overexpression and/or amplification of the EGFR gene or by autocrine /paracrine growth factor loops, whereas activating dimerized mutations promote EGFR signaling, which lead to ligand-independent (Zandi et al., 2007; Laisney, 2013). Phosphorylation of this oncogenic receptor at residues Tyr845, Tyr1045 and Tyr1173 leads to receptor activation and downstream signaling (Glynn et al., 2010; Kim, 2015). Oncogenic receptor EGFR (George Zhu, 1993-2010, 2013, 2015; Al-Nedawi et al., 2008; Laisney, 2013; Ullrich, 1992; O'Connor, 2008; Gabitova, 2014) was found to be involved in A431 human carcinoma cells (Shimizu et al., 1982; Merline et al., 1984; Ullrich et al., 1984; Santon et al., 1986), squamous cell carcinoma (SSC) (Kamata et al., 1986), epithelial cell lines from mammary carcinoma (Minke et al., 1991), glioblastoma stem cells (George Zhu et al., 2013; Lee et al., 2006; Miltra, et al., 2009), EGFR+++ positive in one glioma, (George Zhu, 2013), and colorectal carcinoma tissue (Hembrough, 2012). Oncogenic EGFR mutations are found in 10% to 35% of lung adenocarcinomas, with predominant in a subset of patients with non-small cell lung cancer (NSCLC) (Godin- Heymann et al., 2007; Rosell et al., 2011; Karachalion et al., 2014).

These mutations, which commonly occur as either small in-frame deletions in exon19 or point mutations T790M and L858R in exon21 within the EGFR tyrosine kinase domain, confer constitutive activity and sensitivity to EGFR tyrosine kinase inhibitors (TKI) (Gallant et al., 2015; Konduri et al., 2016). Recent, Gallant (Gallant et al., 2015) identified a novel EGFR alteration in lung cancer: EGFR exon18-25 kinase domain duplication (EGFR-KDD). EGFR-KDD is oncogenic and oncogenic EGFR-KDD-transformed cells are sensitive to the

EGFR TKI afatinib. Konduri and colleagues (Konduri et al., 2016) reported five patients with metastatic lung cancer whose tumors harbored EGFR fusion, most commonly RAD51, are recurrent in lung cancer. Four of whom were treated with EGFR TKI erlotinib with documented antitumor response for 5, 6, 8, and 20 months respectively. These patients whose tumors harbored EGFR fusions are oncogenic in preclinical studies. In mouse model, transgenic mice expressing EGFR L858R in type II pneumocytes developed atypical adenomatous hyperplasia and multifocal adenocarcinoma, and gefitinib inhibited tumorigenesis completely (Ichihara, et al., 2009). Blesa (Blesa et al., 2013) present a durable complete remission of a relapsed glioblastoma with a complete radiologic response and the combination of cetuximab and bevacizumab in a third-line setting, that has offered a progression-free survival of 20 months. In Cuba, CimaVax-EGF, promising, an active vaccine targeting EGF as the major ligand of EGFR, it is in use as a cancer therapy against non-small-cell lung cancer (NSCLC) (Rodriguez et al., 2010; Gonzalez et al., 2011).

PDGFRA mutations are oncogenic (tumorigenic) and developed 100% of mice with brain tumors whereas only one of 19 mice implanted with cells overexpressing wild-type PDGFRA developed into brain tumor in vivo (Paugh et al., 2013; Yamada et al., 2006). This D842V mutant was effectively inhibited by crenolanib, a specific inhibitor of PDGFRA and PDGFR β . Golub (Golub et al., 1994) identified that PDGF receptor β is oncogenic in pathogenesis of chronic myelomonocytic leukemia with t(5;12) chromosomal translocation, targetable oncogenic receptor tyrosine kinases PDGFRA/PDGFR β , and FGFR fusions (Mizuki et al., 2008; Lierman et al., 2007; Holzmann et al., 2012; Mcgee, 1988; Oda et al., 2004) in diverse cancers have made some major progress. For example, these hypereosinophilia (HES) patients with FIP1L1/PDGFR α have excellent responses to imatinib treatment (Apperley et al., 2002; Cools et al., 2003; Klion et al., 2007; Jovanovic et al., 2007; Helbig et al., 2008; Arefi et al., 2012). At present, Imatinib, a selective inhibitor of ABL, KIT, and PDGFRA/B, is the first line target therapy for gastrointestinal stromal tumor (GIST) (Kuroiwa et al., 2005).

Hepatocyte growth factor (HGF), like other growth factors, has different effect in different cells. HGF regulates cell growth, cell mortality and morphogenesis by acting a tyrosine signaling cascade after binding to the proto-oncogenic receptor for HGF (HGFR, also proto-oncogenic receptor c-met, met receptor) (MacDougall et al., 2005; Spee et al., 2007; Fieten et al., 2009; Nakamura et al., 2011).

HGF enhances hepatocyte growth, potently suppresses apoptotic death of hepatocytes and decreases serum bilirubin and serum ALT (alanine aminotransferase), which provide therapeutic action of HGF, including severe hepatitis, fulminant hepatic failure (Ishiki et al., 1992) and liver cirrhosis (Matsuda et al., 1995).

HGF-HGF receptor (met oncogenic receptor) signaling stimulate growth of mouse C127 cells transformed phenotype (Jeffers et al., 1996), Caki-1 (a human kidney clear cell carcinoma cell line), U87-MG (a glioblastoma cell line) (Olwill et al., 2013), canine osteosarcoma cells (Fieten et al., 2009), and human hepatoblastoma cells (Goyal et al., 2013), and AML (Kentis et al., 2012).

In vitro HGF can transform immortalized mouse liver epithelial cells (Kanda et al., 1993). Serum HGF levels are elevated in patients suffering from chronic hepatitis and liver cirrhosis (Tomiya, 1992). Moreover, hepatocytes from transgenic mice expressing HGF grew more rapidly than did those from normal siblings. In vivo, Fao HGF cells produced tumors when transplanted into nude mice (Shiota et al., 1992). These conditions cause persistent hepatocellular damage and regeneration; consequently, there are associated with the subsequent of hepatocellular carcinoma (HCC). Thus, HGF-HGF receptor signaling might play an important role in carcinogenesis (Goyal et al., 2013, Gentile et al., 2008). PRS-110 (starting at 0.8mg/kg and going up to 30mg/kg) specifically binds to Met receptor with high affinity and blocks HGF interaction on ligand-dependent (U87-MG) and ligand-independent (Caki-1) xenograft model (Olwill et al., 2013). Animals were randomized for the treatment with a novel met inhibitor EMD 1214063 (50mg/kg/d), which resulted in a complete regression of the sensitive H1112L met variant-derived tumors (Medova et al., 2013). Foretinib, the first multi-target c-met TKI to under clinical investigation, produced a promising benefit in HCC patients (Goyal et al., 2013). Recently, the chemically-modified monovalent antibody DN30 was found to inhibit ligand-independent activation of the met oncogenic receptor, providing another target therapy (Gual et al., 2001; Vigna et al., 2014 and 2015).

Cytokine receptors had oncogenic mutant variants in cancer

Growth hormone (GH)/oncogenic GH receptor (GHR) (Lobie, 2004; Conway-campbell et al., 2007; Lincoln et al., 2000; Yash et al., 2014) was associated with growth hormone receptor deficiency (Rosenbloom et al., 1999) gigantism, acromegaly and cancer risk (Palmiter et al., 1982; Orian, et al., 1990; Orme et al., 1998; Beuschlein et al., 2000; Tornell, et al., 1991); GHR determines 'cancer-like' features (Yash et al., 2014). GH-releasing hormone GHRH/GHRH receptor oncogenic signaling (Mayo et al., 1988; Asa et al., 1992). Insulin/insulin receptor/Ros

proto-oncogenic receptor homologue, and IGF-I, IGF-II/ oncogenic receptor PTK IGF-IR linked to physiology and diseases (short status, oncogenic transformation process) (Wang et al., 1987; Zong et al., 1998; Kaleko et al., 1990; Giorgino et al., 1991; Hankinson et al., 1998; Jones et al., 2007; Carboni et al., 2005; Pisani, 2008); and IGF-I (Mecasermin) replacement therapy (Klinger & Laron, 1995; Rosenbloom, 2009; Ranke et al., 1999). Interesting, the oncogenic mechanism in Ewing sarcoma harboring oncogenic EWS/NR4A3 fusion involves a novel pro-oncogenic IGF/IGF-1 receptor signaling pathway including post-transcriptional derepression of IGF signaling by the EWS/Flil1 fusion oncoprotein via miRs (McKinsey, 2011), and this provide therapeutic targeting anti-IGF-1 receptor antibody in Ewing Sarcoma (Naing et al., 2012; Tap et al., 2012; Sommer et al., 2016).

G-CSF (filgrastim) has been used in clinic for more than 2 decades to treat congenital and acquired neutropenias (Kostmann et al., 1975; Dale et al., 1993; Hubel et al., 2002; Zeidler et al., 2000; Donini et al., 2007; Rosenberg et al., 2010). It is highlight the clinical application of G-CSF to children with severe congenital neutropenia (SCN) and especially in patients with neutropenia harboring in the G-CSF receptor (CSF3R) gene, which is correlated to an increased risk for development of MDS and acute myeloid leukemia (AML) (Beekman & Touw, 2010). There are two classes of CSF3R mutant variants: truncations of the cytoplasmic domain (Germeshausen et al., 2007; Beel et al., 2009) and membrane proximal point mutations including T618I (Fleischman et al., 2013). Truncated CSF3R mutations are the mutant type nearly almost observed in SCN and abnormal signaling of this oncogenic receptor variants in malignant transformation, whereas membrane proximal mutations (particularly T618I) are the predominant mutation type observed in chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL negative) chronic myeloid leukemia (aCML), and confer ligand-independent growth (Fleischman, et al., 2013). Maxson and colleagues (Maxson et al., 2013) identified activating mutations for CSF3R in 59% (16/27) of patients with CNL or atypical CML. In vivo, the activating mutation in the CSF3R gene induces hereditary chronic neutrophilia (Plo et al., 2009). Mice transplanted with CSF3R T618I-expressing hematopoietic cells developed a myeloproliferative disorder (Fleischman et al., 2013). Treatment with the JAK inhibitor ruxolitinib lowered the white blood cells and reduced spleen weight. These results indicate that activating mutant CSF3R is oncogenic (Maxson et al., 2013) and sufficient to drive a myeloproliferative disorder resembling CML and CNL that

is sensitive to pharmacologic JAK inhibition (Fleischman et al., 2013).

Another more example is that a translocation t(14;19)(q32;p13) was involved IGH@ and the cytokine receptor EPOR at 19P13 in two patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) (Russell et al., 2009; Iacobucci et al., 2014, 2016). An over 230- and 241-fold increase in the expression of EPOR were observed in 2 patients at diagnostic and relapse samples respectively. The EPOR-IGH/IGK chain fusions result in truncation of the cytoplasmic tail of EPOR at residues similar to the mutant EPOR in PFPC, with preservation of the proximal tyrosine essential for receptor activation and loss of distal regulatory residues. Expression of truncated EPOR in mouse B cell progenitors induced ALL in vivo. The data implicate oncogenic erythropoietin receptor in role of both benign erythrocytosis and malignancy (Longmore et al., 1993; de la Chapelle, 1993). Moreover, mutation of erythropoietin receptor (EPOR) gene was associated with primary familial and congenital polycythemia (PFPC). Truncated mutations of 59 to 84 amino acids of EPOR at c-terminus lead to loss of the intracellular cytoplasmic tail of the receptor, and prolonged proliferative signal resulting in hypersensitivity (5-10 fold increased sensitivity) to erythropoietin, and prolonged activity of JAK2 kinase and STAT5 activity (Arcasoy et al., 2002; Forget et al., 2000; Perrotta et al., 2010). The leukemic cells with oncogenic EPOR fusions were sensitive to JAK-STAT inhibition, suggesting a therapeutic option in high-risk ALL.

Accumulated studies, constitutive activation of cytokine interleukin-2 (IL-2) gene can induce autocrine growth of IL-2-producing leukemic cells in adult T-cell leukemia (Maruyama et al., 1987), in vitro transformation and tumorigenicity of T cells (Yamada et al., 1987; Karasuyama et al., 1989; Nagarkatt et al., 1994; Hassuneh et al., 1997), and tumour cells bearing IL-2-BCM fusion in a T cell lymphoma with t(4;16)(q26;p13) translocation (Laahi et al., 1992). IL-2 binds to IL-2 receptor α (IL-2Ra) and subunit of the IL-2 receptor (IL-2RG) sharing with other cytokine receptor superfamily (including IL-7 receptor, IL-21 receptor) that receptor complex transduces growth and differentiation signals (Goldsmith et al., 1995). Under physiological condition, IL-2 appears to act on antigen-specific proliferation of T lymphocytes, immune thymocytes, B-lymphocytes, natural killer cells (NK cells) and lymphokine-activated killer cells (LAK cells), which linked to adoptive immune therapy (Rosenberg et al., 1985).

In vitro nude mice, fibroblasts transfected with a chimera molecule containing the extracellular IL-2 binding domain of the IL-2R cDNA and the transmembrane and intracellular kinase domain of the EGF receptor cDNA, were morphologically

transformed and produced rapidly growing tumor (Bernard & Ullrich, 1987). Moreover, retroviral expression of IL-2RG restore signaling by IL-7 receptor to X-SCID precursor cells in T-cell progression to the pro-leukemic effects of ectopic LMO2 (Pike-Overzet, 2006). Recently, the chromosomal translocation t(5;9)(q13;q22) in peripheral T cell lymphoma generating the interleukin 2 inducible T cell kinase (ITK)-spleen tyrosine kinase (SYK) fusion kinase mimics a T-cell receptor signal and drives oncogenesis in mouse models (Pechloff, 2010).

Activation of the interleukin-3 (IL-3) gene by the enhancer of the IgH fusion leads to the overexpression of IL-3 gene product in 2 cases of acute lymphocytic leukemia with t(5;14)(q31;q21) translocation (Grimaldi & Meeker, 1989, 1990). Serum IL-3 correlated with the clinical course. When the patient's leukemic cell burden was highest (WBC 116,500/ul, lymphoblasts 33,785/ul), the serum IL-3 level was highest (799,5 pg/ml); whereas complete remission (WBC 123,00/ul, lymphoblasts 0/ul), serum IL-3 levels decreased to 105,1 pg/ml. Therefore, overexpression of IL-3 gene coupled with the presence of aberrant IL-3 receptor in these cells could account for oncogenic effects of proliferative advantage and may play a central role in the pathogenesis of leukemia (Grimaldi et al., 1990; Steelman et al., 1996). Aberrant presence of cysteine residues was shown to induce homodimerization of mutant interleukin-7 receptor (IL-7R), which drive constitutive signaling via JAK1 and independently of IL-7, rc or JAK3 (Durum, 2014), promoting cell transformation. This abnormality is involved in ~10% human pediatric T-cell leukemogenesis, paving the way for therapeutic targeting oncogenic IL-7R-mediated signaling in T-ALL (Sasson et al., 2006; Shochat et al., 2014; Mansour et al., 2013). Interleukin-21 receptor (IL-21R) is capable of signal transduction through homodimerization or potentially heterodimerization with IL-2R gamma. IL-21 and IL-21R not only regulates proliferation of mature B cells and T cells in response to activating stimuli but also mediate expansion of NK population from bone marrow. The gene for IL-21R is found the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma and a lymphoma cell line YM (Ueda et al., 2002). This IL-21R/BCL6 fusion gene is clearly associated with lymphoid cell origin.

Conclusion

To date, antibodies that target oncogenic receptors are often targeted toward lysosome (Moody et al., 2015) or blockade of translocation from the endoplasmic reticulum to the cell surface of specific antigens such as vascular endothelial growth factor receptors (VEGFR2) or Tie2 (Kirschning et

al., 2010). For instance, targeting cells with biotinylated ligands and addition of streptavidin efficiently targets trastuzumab to lysosome and this crosslinking of trastuzumab increased lysosomal degradation of its cognate oncogenic receptor Her2 in breast cancer cell lines (Moody et al., 2015). Another burgeoning class of targeted chemotherapies called antibody-drug conjugates (ADCs). This ADCs that have demonstrated sufficient efficacy to gain and retain clinical approved are ado-trastuzumab emtansine (brand name Kadcyla) and brentuximab vedotin (brand name Adcetris) (Ornes, 2013). The auristatin-based antibody-drug conjugate BAY1187982 is for the treatment of FGFR2-positive solid tumors (Sommer, 2016). Another, the nicotinic acetylcholine receptor $\alpha 7$ -nAChR (toxicology) is the oncogenic receptor, which mediated nicotine (NNK and NNN) oncogenic signaling in an important role in the initiation and progression of cancer including lung cancer and this oncogenic response was in parallel with the mutagenic and cytotoxic effects of tobacco smoke to promote the growth and angiogenesis of the tobacco related cancers (Zhao, 2016). Thus nAChRs yield new targets for the prevention and treatment of tobacco related cancers. Thus, down regulating oncogenic receptors may be useful paradigm and perspective in currently the third-line setting of clinical target therapy and in rendering our better understanding of cancer biology (Woodman, 2016; George Zhu, 2014).

Conflicts of interest

The author(s) declare(s) that there is no conflict of interest regarding the publication of this paper.

Acknowledgement

We wish to thank Prof. T. Taniguchi in University of Tokyo in Japan, Nobel Laureates Prof. Ferid Murad in University of Texas Health Center in USA and UNESCO Science Laureates Prof. Atta-ur-rahman in international center for chemical and biological sciences, university of karachi in Pakistan for their valuable help.

References

- Abramson W, Warshawsky H. 1948. Cancer of the breast in the male secondary to estrogenic administration. Report of a case. *J Urol*, 59:76-79.
- Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J (2008). Intracellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumor cells. *Nat Cell Biol*, 10(5): 619-24.
- Althuis MD, Fergenbaum JH, Garcia-Closas M, Sherman ME. 2004. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. *Cancer Epidemiology Biomarkers and Prevention*, 13(10):1558-68.
- Apperley JF, Gardenbas M, Melo JV et al. 2002. Response to imatinib mesylate in patients with chronic myeloproliferative disorders with rearrangements of platelet-derived growth factor receptor beta. *N Engl J Med*, 347:481-7.
- Arcasoy MO, Karayal AF, Segal HM, Sinning JG, Forget BG. 2002. A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. *Blood*, 99:3066-9.
- Arefi M et al. 2012. Response to imatinib mesylate in patients with hypereosinophilic syndrome. *International Journal of Hematology*, 96:320-6
- Asa SL, Kovacs K, Stefanian L et al. 1992. Pituitary adenomas in mice transgenic for growth hormone- releasing hormone. *Endocrinology*, 131:2083-9
- Beekman R, Touw IP. 2010. G-CSF and its receptor in myeloid malignancy. *Blood*, 115:5131-36.
- Beel K, Vandenberghe P. 2009. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute leukemia or myelodysplasia. *Haematologica*, 94:1449-52.
- Bento C. 2013. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases. *Eur J Hematol*, 91:361 -8.
- Berger R et al. 2004. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. *Cancer Res*, 64:8867-75.
- Bernard O, Ullrich A. 1987. High-affinity interleukin 2 binding by an oncogenic hybrid interleukin 2-epidermal growth factor receptor molecule. *PNAS*, 84:2125-9.
- Beuschlein F et al. 2000. Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. *N Engl J Med*, 342:1871-76
- Blesa GJM et al. 2012. Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab. *Case Rep Oncol*, 5:676-81.
- Bocchinofuso WP, Korach KS. 1997. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. *J Mamm Gland Biol Neoplasia*, 2:323-34
- Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althus MD, Mabie JE, Westhoff CL. 2004. Ovarian cancer risk after the use of ovulation-stimulating drugs. *Obstet Gynecol*, 103(6):1194-203.
- Brown GL, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curtsinger LJ 3rd, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. 1989. Enhancement of wound healing by topical treatment with epidermal growth factor. *N Engl J Med*, 321(2): 76
- Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, Pelicci PG, and Minucci S. 2006. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoid acid receptor fusion protein. *Molecular and Cellular Biology*, 26(4):1288-96.
- Cavalieri EL, Rogan EG, Chakravarti D. 2002. Initiation of cancer and other diseases by catechol ortho-quinones: a unifying mechanism. *Cell Med Life Sci*, 59:665-681.
- Chandrasekaran M, Ramadevi K. 2013. Thyromegaly and iodine

- nutritional status in a tertiary care hospital in South India. *Indian J Endocrinol Metab*, 17:260-4
- Choi JH, Choi KC, Auersperg N, Leung PCK. 2004. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. *J Clin Endocrinol Metab*, 89:5508-5516.
- Choi WJ, Kim J. 2014. Dietary factors and risk of thyroid cancer: a review. *Clin Nutr Res*, 3(2):75-88.
- Chomienne C, Ballerioi P, Balitrand N, Huang ME, Krawice I, Castaigne S, Fenaux P, Tioillais P, Dejean A, Degos L, de The H. 1990. The retinoic acid receptor gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. *Leukemia*, 347:558.
- Clarke RB. 2004. Human breast cell proliferation and its relationship to steroid receptor expression. *Climateric*, 7:12.
- Cohen S, Ushiro B, Stoscheck C, Stoscheck C, Chinkers M. 1982. A native 170,000 epidermal growth factor receptor kinase complex from shed membrane vesicles. *J Biol Chem*, 257:1523-31.
- Coindet J. 1821. Nouvelles recherches sur les effets de l'iode, et sur les cautions surverre dansle traitement du goitre par ce nouveau remide. *Ann Chimie Phys*, 16:252-266.
- Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons PG, Jans DA, Waters MJ. 2007. Nuclear targeting of the growth hormone reseptor results in dysregulation of cell proliferation and tumorigenesis. *Proc Natl Acad Sci USA*, 104: 13331-64.
- Cools J, DeAngelo DJ, Gotlib J et al. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIPIL1 gene as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med*, 348:1201-14.
- Corcos D, Osborn MJ, Matheson LS. 2011. B-cell receptors and heavy chain diseases:guilt by association?. *Blood*, 117:6991-8.
- Corcos D. 1990. Oncogenic potential of the B-cell antigen receptor and its relevance to heavy chain disease and other B-cell neoplasias:a new model. *Research in immunology*, 140:543-53.
- Couse JF, Davis VL, Hanson RB, Jefferson WN, McLachlan JA, Bullock BC, Newbold RR, Korach KS. 1997. Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to DES. *Mol Carcinog*, 19:236-242.
- Cui YZ, Onozawa M, Garber HR, Samsel L, Wang Z, McCoy JP, Burkett S, Wu X, Aplan PD, Mackall C. 2015. Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in thymus induces T-ALL. *Blood*, 125(19): 2958-67.
- Culing Z, et al., 1993. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adenal androgens and progesterone. *Mol Endocrinol*, 7:1541-50.
- Cunha GR, Chung LWK. 1981. Stromal-epithelial interactions-I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. *Journal of Steroid Biology Chemistry*, 14: 1317-24.
- Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, Wang W, Jakubowski A, Winton E, Lalezari P. 1993. A randomized controlled phase III trial of recombinant human granulocyte colony stimulating factor(filgrastim) for treatment of severe chronic neutropenia. *Blood*, 81:2496.
- Davey MP. 1988. Juxtaposition of the T-cell receptor alpha-chain locus(14q11) and a region(14q32) of potential importance in leukemogenesis by a 14:14 translocation in a patient with T-cell chronic lymphocytic leukemia and ataxia-telangiectasia. *Proc Natl Acad Sci USA*, 85:9287-91.
- Davis, VL et al. 2012. Expression of a dominant negative estrogen receptor alpha variant in transgenic mice accelerates uterine cancer induced by the potent estrogen diethylstilbestrol. *Reprod Toxicol*, 34:512-21.
- De Braekeleer E, Douet-Guilbert N, De Braekeleer M. 2014. RARA fusion genes in acute promyelocytic leukemia:a review. *Expert Rev Hematol*, 7:347-57.
- de la Chapelle A. 1993. Truncated erythropoietin receptor cause dominantly inherited benign human erythrocytosis. *PNAS*, 90:4495-99.
- de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean. 1991. The PML-RARA fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell*, 66:675-684.
- Denny CT et al. 1986. A chromosomal 14 inversion in a T-cell lymphoma is caused by site-specific recombination between Ig and T-cell receptor loci. *Nature*, 320:549-51.
- Dickson RB, Stancel GM. 2010. Estrogen receptor-mediated processes in normal and cancer cells. In Cavalieri E and Rognan E(eds). *JNCI Monograph:estrogen as endogenous carcinogens in breast and prostate*. Oxford University Press, Oxford, pp 135 -145.
- Dickson RB, McManaway ME, Lipman ME. 1986. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. *Science*, 232:1540-43.
- Donini M et al., 2007. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. *Blood*, 109:4716
- Dos Santos GA, Kats L, Pandolfi PP. 2013. Synergy against pml-RARa:targeting, transcription, proteolysis,differentiation,and self-renawal in acute promyelocytic leukemia. *J Exp Med*, 210 (13): 2793-802.
- Dos Santos GA, Kats L, Pandolfi PP. 2013. Synergy against pml-RARa:targeting, transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. *J Exp Med*, 210 (13):2793-802.
- Durum SK.2014. IL-7 and TSLP receptors:twisted sisters. *Blood*, 124:106-110.
- Ebisawa T, Tojo K, Tajima N, Kamio M, Oki Y, Sasano H. 2008. Immunohistochemical analysis of 11-beta -hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in

- subclinical Cushing's disease due to pituitary macroadenoma. *Endocrine Pathology*, 19:252-60.
- Elangovan S, et al. 2011. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. *Cancer Res*, 71:6654-64
- Fieten H, Spee B, Ijzer J, Kik MJL, Penning LC, Kirpenstein J. 2009. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. *Veterinary Pathology*, 46:869-77.
- Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW. 2013. The CSF3R T618I mutation cause a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. *Blood*, 122:3628-31.
- Forget BG, Degan BA, Arcasoy MD. 2000. Familial polycythemia due to truncations of the erythropoietin receptor. *Trans Am Clin Climatol Assoc*, 111:38-44.
- Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA, Flaws JA, Furth PA. 2005. Deregulated estrogen receptor α expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. *Cancer Res*, 65(3):681-5.
- Friedman DR, Weinberg JB. 2013. Inhibition of B-cell receptor signaling as a therapeutic strategy for treatment of CLL. *The Haematologist*, 13:5.
- Fuqua SAW, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hoppe T, Hilsenbeck S, Mohsin S, O'connell P, Allred DC. 2000. A hypersensitive estrogen receptor- α mutation in premalignant breast lesions. *Cancer Res*, 60:4026-9
- Gabitova L, Gorin A, Astsaturov I. 2014. Molecular pathways:sterols and receptor signaling on cancer. *Clin Cancer Res*, 20(1): 28-34.
- Gallant JN, Sheehan JH. (2015) EGFR kinase domain duplication(EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. *Cancer Discov*, 5(11):1155-63.
- Gentile A, Trusolino L, Comoglio PM 2008 The Met tyrosine kinase receptor in development and cancer. *Cancer Metastasis Rev*. 27(1):85-94
- George Zhu. 1989-91. Oncogenic receptor hypothesis. *VOA (Voice of America)*, 1992, 12:31.
- George Zhu, Ali-AKbar Saboor-Yaraghi. 2015. In oncogenic receptor from molecular physiology to diseases. Abstract in BIT's 8th Annual World Cancer Congress-2015, May 15-17, pp.494 (www.bitlifesciences.com)
- George Zhu, Dong JX, Dharmadhikari D. 2013. In, Natural products from traditional medicine antitumor compound in advanced cancers, proceeding of BIT's 11th Annual Congress of International Drug Discovery Science and Technology- 2013, November 13-16, pp 477.
- George Zhu, Mische SE, Seigner B. 2013. Novel treatment of acute promyelocytic leukemia: As2O3, retinoic acid and retinoid pharmacology. *Curr Pharm Biotechnol*, 14(9):849-858.
- George Zhu, Musumeci F, Byrne P. 2013. Induction of thyroid neoplasm following plant medicine marine algae(sargassum):a rare case and literature. *Curr Pharm Biotechnol* 14:859-863.
- George Zhu, In. Discovery of the molecular basis of retinoic acid action (retinoid signaling)-A genetic regulation of eukaryotes in transcription. proceedings of 3rd biotechnology world congress, Duibai, UAE, February 10-12, 2014, pp 97-98.
- Germeshausen M, Ballmaier M, Walter K. 200. Incidence of CSF3R mutations in SCN and relevance for leukemogenesis: results of a long-term survey. *Blood*, 109:93-99.
- Giltane JM, Balko JM, Stricker TL, Young C, Estrada MV, Wagle N, van Allen E, Mu XJ, Sanchez V, Farley J, Fitzgerald K, Graber A, Pinto JA, Doimi F, Gomez H, Rizzo M, Julian TB, Abramson V, Mayer I, Kelley M, Yenamandra A, Wheeler FC, Sanders M, Garraway L, Meszoely I, Arteaga CL. 2015. Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer. Abstract PD6-3 in Thirty-seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 9-13, 2014, San Antonio, TX. *Cancer Res*, 75(9 supplement): PD6-3.
- Giorgino F, Belfiore A, Milazzo G, Costantino A, Maddux B, Whittaker J, Goldfine ID, Vigneri R. 1991. Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. *Molecular Endocrinology*, 5:452-9.
- Giusti F, Falchetti A, Franceschelli F, et al 2010. Thyroid cancer: current molecular perspective. *J Oncol*, 35:1679.
- Glynn SA, Boerima BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Ambs, S. 2010 Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. *J Clin Invest*, 120(11): 3843-54.
- Goddipati JP. et al 1994. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer. *Cancer Res*, 54:2861-4.
- Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DA. 2007. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. *Cancer Res*, 67(15):7319-26.
- Goldberg RC, Chaikoff IL. 1952. Induction of thyroid cancer in the rats by radioactive iodine. *Arch Pathol*, 53:22-28.
- Goldsmith MA et al. 1995. Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the γ chain. *J Biol Chem*, 270:21729-37.
- Golub TR, Barker GF, Louett M, Gilliland DG. 1994. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal

- translocation. *Cell*, 77: 307-16.
- Gonzalez G, Crombet T, Lage A 2011. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment. *Curr Cancer Drug Target*, 11: 103 – 104.
- Goyal L, Muzamdar MD, Zhu AX, 2013. Targeting the HGF/c-Met pathway in hepatocellular carcinoma. *Clin Cancer Res*, 19:2310-18.
- Green S, Chambon P. 1986. Carcinogenesis. A superfamily of potentially oncogenic hormone receptors. *Nature*, 324:615-617.
- Grignani F, Ferrucci P, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Peschle C, Nicoletti I, Pellicci PG. 1993. The acute promyelocytic leukemia-specific PML-RAR α fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. *Cell*, 74:423-31.
- Grimaldi JC, Meeker TC 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. *Blood*, 73: 2081 – 85.
- Gual P, Giordano S, Anguissola S, Parker PJ, Comoglio PM. 2001. Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. *Oncogene*, 20(2): 156-66.
- Gucalp A. 2013. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. *Clin Cancer Res*, 19:5505-12.
- Hankinson SE et al. 1998. Circulating concentrations of IGF-1 and risk of breast cancer. *Lancet*, 351:1391-96.
- Harris SE, Rong Z, Harris MA, et al 1990. Androgen receptor in human prostate carcinoma LNCaP/Adep cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region (abstract). In: Bell L, editor. *Proceedings of the 72nd Annual Meeting of the Endocrine Society: Atlanta(GA). Bethesda (MD): The Endocrine Society.*
- Hassuneh MR, Nagarkatti PS, Nagarkatti M. 1997. Evidence for the participation of interleukin-2 (IL-2) and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin. *Blood*, 89:610-20.
- Hauksdotti H, Privalsky ML. 2001 DNA recognition by the aberrant retinoic acid receptor implicated in human acute promyelocytic leukemia. *Cell Growth Differ*, 12(2):85-98.
- Helbig G. 2008. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukemia in FIPIL1-PDGFR α -expressing patients. *Br J Haematol*, 41: 200- 4.
- Hembrough T, Thyparambil S, Liao WL, Darfler M, Krizman D, Adms R, Burrow J. 2012. Quantitative multiplexed SRM analysis of oncogenic receptors in FFPE colorectal carcinoma tissue. AACR 103rd Annual Meeting 2012-Mar31-April4, 2012, Chicago, IL. *Cancer Res*, 72:5537.
- Herynk MH et al. 2010. A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interaction. *Breast Cancer Res Treat*, 122:381-93.
- Holzmann K, Grunt T, Heinzle C, Sampl S, Steinhoff H, Reichmann N, Kleiter M, Hauck M, Marian B. 1988. Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. *J Nucleic Acids*, 2012(15): 950508.
- Horn-Ross PL, Morris JS, Lee M, et al. 2001. Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. *Cancer Epidemiol Biomarkers Pre*, 10(9):979-85.
- Houliston RS, Hodges RS, Sharom FJ, Davis JH. 2004. Characterization of the proto-oncogenic and mutant form of the transmembrane region of Neu in micelles. *J Biol Chem*, 279:24073-80.
- Hubel K, Dale DC, Liles WC, 2002. Therapeutic use of cytokines to modulate phagocytic function for the treatment of infectious diseases: current status of G-CSF, GM-CSF, M-CSF, and IFN- γ . *J Infect Dis*, 185:1490-1501.
- Hull ME, Kriner M, Schneider E, Maiman M. 1996. Ovarian cancer after successful ovulation induction: a case report. *J Reprod Med*, 41(1):52-4.
- Humbert M, 2014. The tumor suppressor gene DAPK2 is induced by myeloid transcription factors pu.1 and c-EBP α during granulocytic differentiation but repressed by PML-RAR α in APL. *J Leuk Biol*, 95:83-93.
- Hunter MG, Avalos BR. 2000. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. *Blood*, 95:2132.
- Iacobucci I et al. 2014. Cryptic truncating rearrangement of the erythropoietin receptor in ph-like acute lymphoblastic leukemia. *Blood*, 124:128. Iacobucci I et al. 2016. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. *Cancer Cell*, 29(2):186-200.
- Ichihara E, Takeda H, Kubo T, Hirano S, Yoshino T, Takata M, Tanimoto M, Kiura K. 2009. Chemopreventive effect of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. *Cancer Res*, 69:7088-95.
- Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T. 1992. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and for potent anti-hepatitis action in vivo. *Hepatology* 16: 1227–35.
- Isikbay M et al. 2014. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. *Horm Cancer*, 5(2):72-89.
- Izumi K, Kami A, Lin WJ, Lai KP, Chang CS. 2013. Androgen receptor loss in the development of benign prostate hyperplasia. *The American Journal of Pathology*, 82:1942-9.
- Jacobs H, Ossendorp F, de Vries E et al. 1996. Oncogenic potential of a pre-T cell receptor lacking the TCR β variable domain. *Oncogene* 12:2089-99.

- Jeffers M, Rong S, Anver M, Vande Woude GF. 1996. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastatic phenotype in C127 cells. *Oncogene*, 13:853-6.
- Jenkins PJ. 2006. Cancer associated with acromegaly. *Neuroendocrinology*, 83:218-23.
- Johanssen S, Allolio B. 2007. Mifepristone (RU486) in Cushing's syndrome. *Eur J Endocrinol*, 157(5):561-9.
- Jonckhere et al. 2012. The Mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signaling pathways. *PLoS One*, 7:e32232.
- Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Khokha R, Moorhead RA. 2007. Transgenic overexpression of IGF-1R disrupts mammary ductal morphogenesis and induces tumor formation. *Oncogene*, 26:1636-44. Carboni JM, (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. *Cancer Res*, 65:3181-7.
- Jovanovic JV, Score J et al. 2007. Low-dose imatinib mesylate leads to rapid molecular responses and achievement of complete molecular remission in FIPIL1-PDGFR α -positive chronic eosinophilic leukemia. *Blood*, 109:4635-40.
- Kaleko M, Rutter WJ, Miller AD. 1990. Overexpression of the human insulin like growth factor-1 receptor promotes ligand-dependent neoplastic transformation. *Molecular and Cellular Biology*, 10:464-73.
- Kamata N, Chida K, Rikimaru K, Horikoshi M, Enomoto S, Kuyoki T. 1986. Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture. *Cancer Res*, 46:1648-53.
- Kanda H, Tajima H, Lee GH, Nomura K, Ohtake K, Matsumoto K, Nakamura T, Kitagawa T. 1993. Hepatocyte growth factor transforms immortalized mouse liver epithelial cells. *Oncogene*, 8:3047-53.
- Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, et al. 2014. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. *Transl Lung Cancer Res (TLCR)*, 3(3):122-130.
- Karasuyama H, Tohyama N, Tada T. 1989. Autocrine growth and tumorigenicity of interleukin-2- dependent helper T cells transfected with IL-2 gene. *JEM*, 169:13-25.
- Karl M et al. 1996. Nelson's syndrome associated with somatic frame shift mutation in the glucocorticoid receptor gene. *J Clin Endocrinol Metab*, 81:124-29.
- Kentis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. 2012. Autocrine activation of the Met receptor tyrosine kinase in AML. *Nat Med*, 18:1118-22.
- Kim YJ, Apetri M et al., 2015. Differential effects of tyrosine kinase inhibitors on normal and oncogenic EGFR signaling and downstream effectors. *Mol Cancer Res*, 13:765.
- Kirschning CJ, Dreher S, Maa B, Fichte S, Schade J, Koster M, Boldicke T. 2010. Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-derived cell activation. *BMC Biotechnology*, 10:31.
- Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey CH, Nemeth MJ, Golub TR, Freemantle SJ, Dmitrovsky E. 2002. UBE1L is a retinoid target that triggers pml/RAR α degradation and apoptosis in acute promyelocytic leukemia. *PNAS*, 99:3806-11.
- Klinger B, Laron Z. 1995. Three year IGF-1 treatment of children with Laron syndrome. *J Pediatr Endocrinol Metab*, 8:149-58.
- Klion AD et al., 2007. Relapse following discontinuation of imatinib mesylate therapy for FIPIL1/ PDGFR α -positive chronic eosinophilic leukemia: implications for optimal dosing. *Blood*, 110:3552-6.
- Koivisto PA, et al, 2004. Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer. *J Urol*, 171:431-33.
- Konduri K, 2016. EGFR fusions as Novel Therapeutic Targets in lung cancer. *Cancer Discov*, 6 (6):601-11.
- Kostmann R. 1975. Infantile genetic agranulocytosis: A review with presentation of 10 cases. *Acta Paediatr Scand*, 64:362.
- Krishnan AV, Zhao XY, Swami S, Brive L, Peehi DM, Ely KR. 2002. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen- independent prostate cancer. *Endocrinology*, 143:1889-900.
- Kung HS, Evans CP. 2009. Oncogenic activation of androgen receptor. *Urol Oncol*, 27:48-52.
- Kuroiwa M, Hiwatari M, Hirato J, Suzuki N, Tsuchida Y, Shimada A, Shitara T, Taki T, Hayashi Y. 2005. Advanced-stage gastrointestinal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFR α . *J Pediatr Surg*, 40(11); 1798-801.
- Laabi Y, Gras MP, Carbonnei F, Brouet JC, Berger R, Larsen CJ, Tsapis A. 1992. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16) (q26;p13) translocation in a malignant T cell lymphoma. *EMBO J*, 11:3897-904.
- Laisney JA, Mueller TD, Scharl M, Meierjohann S. 2013. Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loop. *Oncogene*, 32:2403-11.
- Lallemant-Breitenbach V, de Thé H. 2010. A new oncoprotein catabolism pathway. *Blood*, 116: 2200-2201.
- Lee JC, Vivanco I, Beroukhi R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao

- PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK(2006). Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in extracellular domain. *PLoS medicine*,3:e485.
- Levea CM. 1993. A structural and kinetic comparison of proto-oncogenic and oncogenic neu receptors expressed in insect cells. *Receptor*, 3:293-309.
- Liang M, Adisetiyo H, Liu X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. 2015. Identification of androgen receptor splice variants in the pten deficient murine prostate cancer model. *PLoS One*, 10(7):e0131232.
- Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH, Huang CS, Chang KJ, Yao YT. 2006. Differential expression of glucocorticoid receptor in human breast tissue and related neoplasms. *Journal of Pathology*, 209:317-2.
- Lierman E, Lahortiga I, Miegroet HV, Menten N, Maryneri P, Cools J. 2007. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecular inhibitors. *Haematologica*, 92:27-34.
- Lincoln DT, Kaiser HE, Raju GP, Waters MJ. 2000. Growth hormone and colorectal carcinoma: localization of receptors. *In Vivo*, 14:41-9.
- Lobie PE. 2004. The oncogenic potential of autocrine human growth hormone in breast cancer. Twelfth International Congress of Endocrinology, Aug31-Sep4, Lisbon, abstSY199.
- Longmore GD, Pharr P, Neumann D, Lodish HF. 1993. Both megakaryocytopoiesis and erythropoiesis are induced in mice infected with a retrovirus expressing an oncogenic erythropoietin receptor. *Blood*, 82:2386-95.
- MacDougall CA et al. 2005. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in pr-14C. *Prostate*, 64:139-48.
- Maetzel D, Denzel S, Mack B, Eggert C, Barr G, Gires O. 2009. Initial activation of EpCAM cleavage via cell-to-cell contact. *BMC Cancer*, 9:402.
- Mansour MM, et al., 2013. Targeting oncogenic interleukin-7 receptor signaling. *Blood*, 122:2535.
- Marstrand TT et al., 2010. A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. *Leukemia*, 24:1265
- Maruyama M, Shibuya H, Harada H, Hatakeyama M, Seiki M, Fujita T, Inoue JI, Yoshida M, Taniguchi T. 1987. Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering. *Cell*, 48:343-350
- Matsuda Y, Matsumoto K, Ichida T, Nakamura T. 1995. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. *J Biochem*, 118: 643-49.
- Matsumura I, Mizuki M, Kanakura Y. 2008. Roles for deregulated receptor tyrosine kinase and their downstream signaling molecules in hematologic malignancies. *Cancer Science*, 99:479-85.
- Maxson JE, Gollib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeener SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. 2013. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. *N Engl J Med*, 368:1781-90.
- Mayo KE et al. 1988. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. *Molec Endocrinol*, 2:606
- Mcgee GS. 1988. Recombinant basic fibroblast growth factor accelerate wound healing. *J Surg Res*, 45:145.
- McKinsey EL et al. 2011. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathways targeting by EWS/Fil1-regulated microRNAs. *Oncogene*, 30:4910-20.
- Medová M, Pochon B, Streit B, Blank-Liss W, Francica P, Stroka D, Keogh A, Aebersold DM, Blaukat A, Bladt F, Zimmer Y. 2013 The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. *Mol Cancer Ther*, 12(11):2415-24.
- Mehlen P, Bredesen DE. 2004. The dependence receptor hypothesis. *Apoptosis*, 9(1):37-49.
- Melhem A, et al. 2009. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic gene SGK1 and MKP1/DUSP1 in ovarian tissues. *Clin Cancer Res*, 15(9):3196-204.
- Merline GT, Xu YH, Ishii S, Clark AJL, Semba K, Toyoshima K, Yamamoto T, Pastan I. 1984. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. *Science*, 224:417-419.
- Michikawa T, Inoue M, Shimazu T, Sawada N, Iwasaki M, Sasazuki S, Yamaji T, Tsugane S. 2012. Seaweed consumption and the risk of thyroid cancer in women: the Japan Public Health Center-based prospective study. *Eur J Cancer Prev*, 21:254-260
- Mikose CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. 2001. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. *J Biol Chem*, 276:16649-54.
- Miltra S, Han S, Soderstram K, Wong A. 2009. Preferential expression of an oncogenic receptor in brain tumor stem cells: Identification and targeting using an engineered antibody. Abstract #4801 in *Proc Am Assoc Cancer Res*, 18-22, PA.
- Minke JM, Schuurin ED, van den Berghe R et al. 1991. Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptor. *Cancer Res*, 51:4028-31.
- Mirand EA, Reiniard MC, Goltz HL, Moore GE. 1953.

- Development of sarcomas in Marsh-Albino mice following injection of desoxycorticosterone acetate(DCA) in sesame oil. *Proc Soc Exper Biol and Med*, 83:14-17.
- Mizuki M, Ueda I, Matsumura I, Ishiko J, Schwble J, Serve H, Kanakura Y. 2003. Oncogenic receptor tyrosine kinase in leukemia. *Cellular and Molecular Biology*, 49: 907-22.
- Mononen N. et al. 2000. Two percent of Finnish prostate cancer patients have a germline mutation in the hormone-binding domain of the androgen receptor gene. *Cancer Res*, 60:6479-81.
- Moody P, Sayers EJ, Magnusson JP, Alexander C, Borri P, Watson P, Jones AT. 2015. Receptor crosslinking: A general method to trigger internalization and lysosomal targeting of therapeutic receptor:ligand complexes. *Molecular Therapy*, 23(12):1888-98.
- Moutsatsou P, Papavassiliou AG. 2007. The glucocorticoid receptor signaling in breast cancer. *Journal of Cellular and Molecular Medicine*, 12:145-63.
- Mussig K, Thamer C, Bares R, Lipp HP, Haring HU, Gallwitz H. 2006. Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea. *Journal of General Internal Medicine*, 21(6):C11-C14.
- Nagarkatt N et al. 1994. Constitutive activation of the interleukin 2 gene in the induction of spontaneous in vitro transformation and tumorigenicity of T cells. *PNAS*, 91:7638-42.
- Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Kurzrock R. 2012. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. *Clin Cancer Res*, 18(9):2625-31.
- Nakamura T, Sakai K, Nakamura T, Matsumoto K. 2011 Hepatocyte growth factor twenty years on: Much more than a growth factor. *J Gastroenterol Hepatol*, 26 Suppl 1:188-202.
- Nasr R, Guillemain MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H(2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. *Nature Medicine*, 14:1333-42 163.
- Neil JC, Fulton R, McFarlane R, Rigby M, Stewart M, Terry A, Tzavaras T. 1988. Receptor-mediated leukemogenesis: hypothesis revisited. *Br J Cancer*, Supple 9:76-79.
- Newfield RS, Kalaitzoglou G, Licholai T, Chilton D, Ashraf J, Thompson EB, New MI. 2000. Normocorticolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor number. *J Clin Endocrinol Metab*, 85:14-21.
- Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. 1992. Androgen receptor gene mutations in human prostate cancer. *Proc Natl Acad Sci USA*, 89:6319-23
- Nyquist MD, et al. 2013. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. *PNAS*, 110:17492-97.
- O'Connor R. 2008. Concealed cargo within the tumor microenvironment: microvesicles disseminate oncogenic receptors among cancer cells. *Cancer Biol Ther*, 7:1350-1.
- Oda Y, Kagami H, Ueda M. 2004. Accelerating effects of basic growth factor on wound healing of rat palatal mucosa. *J Oral Maxillofac Surg*, 62(1):73-80.
- Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeier M, Trentmann S, Jensen K, Hohlbaum AM, Audoly. 2013. A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. *Mol Cancer Ther*, 12(11):2459-71.
- Orian JM, Tamkoshi K, Mackmy LR, Brandon MR. 1990. New murine model for hepatocellular carcinoma, transgenic mice expressing metallothionein-ovine growth hormone fusion gene. *J Natl Cancer Inst*, 82:393-98.
- Orme SM, McNally RJ, Cartwright RA, Belchetz PE. 1998. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. *J Clin Endocrinol Metab*, 83:2730-34.
- Ornes S, 2013. Antibody-drug conjugates. *Proc Natl Acad Sci USA*, 110:13695.
- Palmiter RD, Brinster RL, Hammer RE, Trambauer ME, Rosenfeld MG, Birnberg NC, Evans RM. 1982. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. *Nature*, 300:611-15.
- Paugh BS1, Zhu X, Qu C, Endersby R, Diaz AK, Zhang J, Bax DA, Carvalho D, Reis RM, Onar-Thomas A, Broniscer A, Wetmore C, Zhang J, Jones C, Ellison DW, Baker SJ. 2013. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. *Cancer Res*, 73:6219-29.
- Perrotta S. 2010. EPO receptor gain-of-function causes hereditary polycythemia, ters CD34 cell differentiation and increases circulating endothelial precursors. *PLoS One*, 5:e12015.
- Pike-Overzet K, de Ridder D, Weerkamp F et al. 2006. Gene therapy: Is IL-2RG oncogenic in T-cell development?. *Nature*, 443:1123.
- Pisani P. 2008. Hyperinsulinoma and cancer, meta-analyses of epidemiological studies. *Arch Physiol Biochem*, 114:63-70.
- Plo I, Zhang Y, Le Couedic JP, Nakatake M, Boulet JM, Itaya M, Smith SO, Debili N, Constantinescu SN, Vainchenkev W, Louache F, de Botton S. 2009. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. *JEM*, 206:1701-1707.
- Podhorecka M, Macheta A, 2013. Acute promyelocytic leukemia-modern approach to disease pathogenesis and differentiation treatment. *Postepy Hig Med Dosw*, 67:1083-9.
- Ranke MB et al. 1999. Long-term treatment of GH insensitivity syndrome with IGF-I. Results of the European multicenter

- study. The working group on growth hormone insensitivity syndrome. *Horm Res*, 51:128-34.
- Richards JS, Farookhi R. 1978. Gonadotrophins and ovarian-follicular growth. *Clin Obstet Gynaecol*, 5:363-73.
- Rietveld LE, Caldenhoven E. 2001. Avian erythroleukemia: a model for corepressor function in cancer. *Oncogene*, 20:3000-9.
- Rietveld LE, Caldenhoven E. 2001. Avian erythroleukemia: a model for corepressor function in cancer. *Oncogene*, 20:3100-9.
- Risch H. 1998. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. *J Natl Cancer Inst*, 90:1774-86.
- Robinson R. 2008. Tumor cells share oncogenic receptors. *J Cell Biol*, 181(4):570.
- Rodriguez PC, Rodriguez G, Gonzalez G, Lage A. 2010. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. *MEDICC Rev*, 12(1):17-2.
- Rosell R et al., 2011. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. *Clin Cancer Res*, 17:1160-8.
- Rosenberg PS et al., 2010. Stable long-term risk of leukemia in patients with severe congenital neutropenia maintained on G-CSF therapy. *Br J Haematol*, 110:196
- Rosenberg SA et al. 1985. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med*, 313:1485.
- Rosenbloom AL et al. 1999. Growth hormone receptor deficiency in Ecuador. *J Clin Endocrinol Metab*, 84:4436-43.
- Rosenbloom AL. 2009. Mecermin (recombinant human insulin-like growth factor IGF-1). *Adv Ther*, 26: 40-54.
- Rousselot P, Hardas H, Patel A, Guidez F, Gaken J, Castaigne S, Dejean A, de The H, Degos L, Farzanch F, Chomienne C. 1994. The PML-RAR α gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. *Oncogene*, 9:545-551.
- Russell LJ, De Cadro DG, Griffiths M et al. 2009. A novel translocation, t(14;19)(q32;p13) involving IGH@ and the cytokine receptor for erythropoietin. *Leukemia*, 23(3):614-17.
- Russo J, Lareef MH, Tahin Q, Hu YF, Slater C, Ao X, Russo IH. 2002. 17 β -estradiol is carcinogenic in human breast epithelial cells. *J Steroid Biochem Mol Biol*. 80(2):149-62.
- Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM, Garber J, Russo IH. 2006. 17 β -Estradiol induces transformation and tumorigenesis in human breast epithelial cells. *FASEBS*, 20:1622-34.
- Russo IH, Russo J. 1998. Role of hormones in mammary cancer initiation and progression. *J Mammary Gland Biol Neoplasia*, 3:49
- Santen R, Cavalieri E, Rogan E, Russo J, Guttenplan J, Ingle J, Yue W. 2009. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. *Ann NY Acad Sci*, 1155:132-140.
- Santon JB, Cronin MT, Macleod CL, Gill GN. 1986. Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. *Cancer Res*, 46:4701-4705.
- Santos J, Mesquita D, Barros-Silva JD, Jeronimo C, Henrique R, Morais A, Paulo P, Teixeira M. 2015. Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements. *Oncoscience*, 2(5):497-507.
- Sasson SC et al. 2006. The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostasis and the challenge facing its utilization as a novel therapy. *Curr Drug Targets*, 7:1571-82.63.
- Schneider DF, Chen H. 2013. New developments in the diagnosis and treatment of thyroid cancer. *CA: cancer J Clin*, 63:373-94.
- Segalla S, Rinaldi L, Kilstruo-Nielsen C. et al. 2003. Retinoic acid receptor a fusion to PML affects its transcriptional and chromatin-remodeling properties. *Mol Cell Biol*, 23:8795-808.
- Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernández-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. 2013. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. *Cancer Discov*, 3(11):1238-44.
- Shi XB, Xue L, Tepper CG, Gandout-Edwards R, Ghoch P, Kung HJ, White DRW. 2007. The oncogenic potential of a prostate cancer-derived androgen receptor mutant. *The prostate*, 67:591-602.
- Shimizu N, Kondo I. 1982. Hyperproduction of EGF receptor in human A431 cell is regulated by a translocation chromosome, t(7;11)(p22;q23). *Cytogenetics and Cell Genetics*, 32:316-317.
- Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. 1992. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. *Proc Natl Acad Sci USA*, 89:373-77.
- Shochat C, Tal N, Gryshkova V, Birger Y, Bandapalli OR, Izraeli S. 2014. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. *Blood*, 124:106-110.
- Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. 1996. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. *Fertil Steril*, 65:13-18.
- Simanainen U, Lampinen A, Henneicke H, et al. 2011. Long-term corticosterone treatment induced lobe-specific pathology in mouse prostate. *Prostate*, 71:289-97.
- Singh RR, Kumar R. 2005. Steroid hormone receptor signaling in

- tumorigenesis. *J Cell Biochem*, 95: 490-505
- Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. 2013. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. *Clin Cancer Res*, 19: 6163-7.
- Skrypek N. 2015. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecin/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug resistance associated protein MRP-2. *Oncotarget*, 6(13):10853-61.
- Sommer A, Kopitz C, Schatz CA, Kreft B. 2016. Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY1187982 for the treatment of FGFR2-positive solid tumors. *Cancer Res*, 2016; DOI:10.1158/0008-5472.
- Southwell J. et al. 2008. An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer. *J Steroid Biochem Mol Biol*, 111: 138-46.
- Spee B, Arends B, van den Ingh T, Roskams T, Rothuizen J, Penning LC. 2007. Major HGF-mediated regenerative pathways are similarly affected in human and canine cirrhosis. *Comparative Hepatology*, 6:8.
- Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. 2001. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. *Proc Natl Acad Sci USA*, 98: 10823-8.
- Stelman LS, Algate PA, Balock WL, Wang XY, Prevost KD, Hoyle PE, McCubrey JA. 1996. Oncogenic effect of overexpression of the interleukin-3 receptor on hematopoietic cells. *Leukemia*, 10: 528-42.
- Strzadala L, Miazek A, Mat uszyk J, Kisielow P. 1996. Role of thymic selection in the development of thymic lymphomas in TCR transgenic mice. *Int Immunol*, 9:127-38.
- Sun SH, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman M, Nguyen HM, Sun HY, Nelson PS, Plymate SR. 2010. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. *J Clin Invest*, 120:2715-30.
- Suzuki H, et al. 1996. Codon 877 mutations in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. *Prostate*, 29:153-8.
- Suzuki H, Higuchi T, Hashimoto H, et al. 1962. A case of endemic goiter along the seashores of Hidaka District, Hokkaido. *Jpn J Med Sci Biol*, 51:781-6.
- Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H. 2015. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. *Transl Res*, 166:e5542.
- Tap WD et al. 2012. Phase II study of ganitumab, a fully human anti-type-1 IGF-1 receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. *J Clin Oncol*, 30:1849-56.
- Taplin ME, et al. 1995. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. *N Engl J Med*, 332:1393-98
- Tekmal RR, et al. 2005. Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice. *J Steroid Biochem Mol Biol*, 95:9-15.
- Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HT. 2002. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. *Cancer Res*, 62:660.
- Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, Furth PA. 2003. Introduction of ERα into the tTA/TA conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. *Am J Pathol*, 163:1713-9.
- Tornell J, Rymo L, Isaksson OG. 1991. Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice. *Int J Cancer* 49:314-7.
- Tzahar E, Yarden Y. 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. *Biochim Biophys Acta*, 1379:M25-37.
- Ueda C, Akasaka T, Kurata M, Maesako Y, Nishikori M, Ichinohasama R, Imada K, Uchiyama T, Ohno H. 2002. The gene for interleukin-21 receptor is the partner of BCL11 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma. *Oncogene*, 21:368-76.
- Ullrich A. 1992. Growth factor receptors in oncogenesis. The American Association for Cancer Research Annual Meeting, 33:589-590.
- Ullrich A, Coussens J, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Liberman TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD, Seeburg PH. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature*, 309:418-25.
- Varricchio L, et al. 2011. The dominant negative beta isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. *Blood*, 118:425-3.
- Veeraraghavan J, Tan Y, Kim JA et al. 2014. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. *Nat Commun*, 5:4577.
- Veldscholte J et al 1990. A mutation in the ligand and binding domain of the androgen receptor of human LNCap cells affects steroid binding characteristics and response to anti-androgens. *Biochem Biophys Res Commun*, 173:534-40
- Vigna E, Chiriaco C, Cignetto S, Fontani L, Basillico C, Petronzelli F, Comoglio PM. 2015. Inhibition of ligand-independent constitutive activation of the Met oncogene

- receptor by the engineered chemically -modified antibody DN30. *Mol Oncol*, Pil: S157.
- Vigna E, Pacchiana G, Chiria C, Cignetto S, Fontani L, Michieli P, Comoglio PM. 2014. Targeted therapy by gene transfer of monovalent antibody fragment the Met oncogenic receptor. *J Mol Med*, 92: 65- 76.
- Vilasco M, Communal L, Mourra N, Courtin A, Forgez P, Gompel A. 2011. Glucocorticoid receptor and breast cancer. *Breast Cancer Res Treat*, 140:1-10
- Wang LH, Lin B, Jong SM, Dixon D, Ellis L, Roth RA, Rutter WJ. 1998. Activation of transforming potential of the human insulin receptor gene. *Proc Natl Acad Sci USA*, 84:5725-29.
- Weir HM, Biadbury RH, Lawson M, etal 2016. AZD9496: An oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1 mutant breast tumors in preclinical models. *Cancer Res*, 76:3307-3318
- Wesledge G, McGuire WL. 1983. Mutations in the estrogen and androgen receptors may contribute to the conversion of steroid-dependent breast tumors and prostate tumors to hormone-independent growth. *Advance Cancer Research*, 38:61.
- Willard MD, Lajiness ME, Wulur IH et al. 2012. Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes. *Molecular Cancer Research*, 10(6):739-749.
- Yamada G, Kitamura Y, Taniguchi T et al. 1987. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. *The EMBO Journal*, 6(9):2705-9.
- Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, Cancelas JA. 2006. The FIPIL1-PDGFR α fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome(HES)/chronic eosinophilic leukemia(CEL)-like disease. *Blood*, 107: 4071-79.
- Yarden Y, Peles E.1991. Biochemical analyses of the ligand for the neu oncogenic receptor. *Biochemistry*, 30(14): 3543-50.
- Yash C, Waters MJ, Brooks A. 2014. The growth hormone receptor mediated oncogenesis. [http:// dx.doi.org/10.14264/uql.2014.478](http://dx.doi.org/10.14264/uql.2014.478).
- Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoz T. 1996. Accelerated degradation of PML-retinoic acid receptor alpha(PML-RAR α) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia, possible role of the proteasome pathway. *Cancer Research*, 56(13): 2945-48.
- Young L, Creevey L, Ali A, Hill ADK and McIlroy M(2015), Investigation into the oncogenic potential of the androgen receptor in aromatase inhibitor resistant breast cancer.(Abstract) in Thirty- Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX. *Cancer Res*, 75(9 supplement): p3-05-21.
- Yue W, Yager JD, Wang JP, Jupe R, Santen RJ. 2013. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. *Steroid*, 78:161-170.
- Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. 2007. Mechanisms for oncogenic activation of the epidermal growth factor receptor. *Cell Signal*, 19: 2013-23.
- Zeidler C et al. 2000. Management of Kostmann syndrome in the G-CSF era. *Br J Haematol*, 109:490.
- Zhao Y. 2016. The oncogenic functions of nicotinic acetylcholine receptors. *Journal of Oncology*, 3:1-9.
- Zhu T, Starling- Emeral B, Zhang X, Lee KO, Gluckman PO, Mertani HC, Lobie PE. 2005. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. *Cancer Research*, 65:317-324.
- Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH. 1998. Stat3 plays an important role in oncogenic ROS- and insulin-like growth factor I receptor-induced anchorage-independent growth. *Journal of Biological Chemistry*, 273: 28065-72.